An Observational Study of Clinical Outcomes and Safety Profile of Galantamine in the Treatment of Patients With Alzheimer's Disease Over an 18-Month Period.
Phase of Trial: Phase IV
Latest Information Update: 08 Jul 2014
At a glance
- Drugs Galantamine (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Janssen-Cilag
- 03 Nov 2009 Actual patient number changed from 56 to 61 as reported by ClinicalTrials.gov.
- 07 Feb 2009 New trial record